CQN-CA-NAX
14.1.2021 09:03:34 CET | Business Wire | Press release
Please replace the logo in the release dated January 13, 2021 with the accompanying corrected logo.
The release reads:
NAX LAUNCHES AS FIRST PLATFORM TO CREATE CORPORATE ASSET-BACKED PRODUCTS, VENTURES AND SECURITIES
- Company founded by Jeff Schumacher
- Company already valued at over $300m USD
New Asset Exchange (NAX), a company that brings liquidity to corporate assets, has formally launched today after two and a half years in stealth development. It has established a new model for launching corporate asset-backed products, ventures and securities. NAX is founded by serial entrepreneur Jeff Schumacher.
NAX combines the software and the method to identify, build, launch and scale asset-backed products, ventures and securitized assets for institutional trading. NAX has secured $65m USD to date in investment from 12 institutional, family office and corporate investors across North America, Europe and Asia, valuing the company at over $300m USD. It launches with a global team based in North America and Europe.
NAX has developed software for digital, micro and platform services, as well as cloud commerce that can be utilized to rapidly market test fully compliant products, tradable securities and marketplaces. The firm will be announcing a series of milestones in the coming months to match its ambitious growth plans.
NAX is already working with leading global businesses in multiple industries including energy, healthcare and consumer goods to launch corporate asset-backed products, and is supported by operating partners from global leaders in trading, banking and underwriting to deliver the requisite infrastructure.
NAX CEO and founder Jeff Schumacher, previously founded and scaled BCG Digital Ventures, with the company becoming one of the largest foundries in the world, creating more than 100 businesses and growing to over 1,000 employees in less than six years. He also founded Axon Advisory Partners, before selling it to Booz & Co., creating Booz Digital, which was then acquired by PwC. Schumacher was previously a Partner at McKinsey, and also EVP, CMO and CSO at Sports Authority, a Leonard Green Partners portfolio company.
Jeff Schumacher, CEO and Founder, NAX said: “We are building upon a decade of learnings from working with the world's leading financial exchanges and institutions. With NAX, we are bringing financial innovation across sectors to create value in markets that otherwise would not exist.”
Since its inception, NAX has attracted several high-profile business figures to its Board, including Frank Strauß, former Global CEO of Private and Commercial Banking at Deutsche Bank, and Heiner Leisten, Leisten & Cie. Family Office CEO and previously Senior Partner at BCG, among others.
Frank Strauß, Independent Board Member, NAX said: “In today’s world, financial innovation is the bedrock upon which successful ventures are created. Jeff’s vision for NAX is what attracted me to supporting the company in applying financial innovation to corporate assets and ultimately unlocking significant value from those assets.”
Francisco Arcilla, Partner, TNF Investments, which led the latest NAX fundraising round, said: “As an international investment firm that prides itself on being a catalyst for innovation and industry disruption, we were instantly captivated by NAX and its disruptive approach to asset creation and value generation. We were very excited to lead the latest round of funding for NAX, and we are equally enthusiastic about the prospect of the many ventures and further investment opportunities that NAX will create.“
NAX operates from its headquarters in Manhattan Beach, CA for North America and Paris, France for Europe, with further locations in Palo Alto, New York, London, and Frankfurt. In 2021, it will be expanding to Singapore, Tokyo and Sydney.
About NAX
NAX is a platform to create asset-backed products, ventures and securities for the world's leading institutions. We co-lead the commercialization of these initiatives with our partners.
For more information, visit http://www.naxgrp.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom